Lung cancer is the most common malignancy in the world, accounting for 13% of all documented cancer cases, of which 85% are non–small cell lung cancer (NSCLC). NSCLC is often diagnosed at an advanced stage, as 56% of patients present with distant metastases.\textsuperscript{31} The 5-year survival for NSCLC is 19.3% overall but decreases to 4.1% with distant metastases.\textsuperscript{15}

Intracranial metastases occur in an estimated 30%--40% of patients with NSCLC and are often identifiable at the time of primary diagnosis.\textsuperscript{5,18,23} The presence of intracranial metastases is invariably associated with a decrease in median survival across all cancer types.\textsuperscript{10} The median survival for a patient with NSCLC and intracranial metastases who forgoes treatment is reportedly less than 2 months. The addition of fractionated whole-brain radiation therapy (WBRT) increases survival to only 3--6 months.\textsuperscript{4,6}

Gamma Knife radiosurgery (GKRS) has proven to be a low risk and effective treatment strategy for a wide variety of patients with brain metastases. The local tumor control after SRS in NSCLC patients consistently exceeds 80% in the literature.\textsuperscript{24,30} The utilization of SRS for NSCLC metastases has increased significantly and appropriately.

**Gamma Knife radiosurgery for the management of cerebral metastases from non–small cell lung cancer**

Greg Bowden, MD, MSc,\textsuperscript{1,3,5} Hideyuki Kano, MD, PhD,\textsuperscript{1,3} Ellen Caparosa, BS,\textsuperscript{4} Seong-Hyun Park, MD, PhD,\textsuperscript{1,3} Ajay Niranjan, MCH, MBA,\textsuperscript{1,3} John Flickinger, MD,\textsuperscript{2,3} and L. Dade Lunsford, MD\textsuperscript{1,3}

Departments of \textsuperscript{1}Neurological Surgery and \textsuperscript{3}Radiation Oncology, and \textsuperscript{2}Center for Image-Guided Neurosurgery, \textsuperscript{4}University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; and \textsuperscript{5}Department of Neurological Surgery, University of Western Ontario, London, Ontario, Canada

**OBJECT** Non–small cell lung cancer (NSCLC) is the most frequent cancer that metastasizes to brain. Stereotactic radiosurgery (SRS) has become the management of choice for most patients with such metastatic tumors. Therefore, the authors endeavored to elucidate the survival and SRS outcomes for patients with NSCLC metastasis at their center. **METHODS** In this single-institution retrospective analysis, the authors reviewed their experience with NSCLC metastasis during a 10-year period from 2001 to 2010. Seven hundred twenty patients underwent Gamma Knife radiosurgery. A total of 1004 SRS procedures were performed, and 3143 tumors were treated. The NSCLC subtype was adenocarcinoma in 386 patients, squamous cell carcinoma in 111 patients, and large cell carcinoma in 34 patients. The median aggregate tumor volume was 4.5 cm\textsuperscript{3} (range 0.1--88 cm\textsuperscript{3}).

**RESULTS** The median survival time after diagnosis of brain metastasis from NSCLC was 12.6 months, and the median survival after SRS was 8.5 months. The 1-, 2-, and 5-year survival rates after SRS were 39%, 21%, and 10%, respectively. Postradiosurgery survival was decreased in patients treated with prior whole-brain radiation therapy compared with SRS alone (p = 0.003). Aggregate tumor volume was inversely related to survival after SRS (p < 0.001), and the histological subgroups demonstrated significant survival differences (p = 0.023). The overall local tumor control rate in the entire group was 92.8%. One hundred seventy-four patients (24%) underwent repeat SRS for new or resistant metastatic deposits.

**CONCLUSIONS** Stereotactic radiosurgery is an effective means of providing local control for NSCLC metastases. Neurological function and survival benefit from serial patient monitoring and repeat SRS for new tumors.

**KEY WORDS** non–small cell lung cancer; lung cancer; metastasis; stereotactic radiosurgery; Gamma Knife; brain; oncology


**ABBREVIATIONS** GKRS = Gamma Knife radiosurgery; KPS = Karnofsky Performance Scale; NSCLC = non–small cell lung cancer; RPA = recursive partitioning analysis; RTOG = Radiation Therapy Oncology Group; SRS = stereotactic radiosurgery; WBRT = whole-brain radiotherapy.

**SUBMITTED** May 18, 2014. **ACCEPTED** December 2, 2014.

**INCLUDE WHEN CITING** Published online February 6, 2015; DOI: 10.3171/2014.12.JNS141111.

**DISCLOSURE** Dr. Lunsford is a consultant for and owns stock in AB Elekta, Stockholm, Sweden.
since the turn of the century. In this study, we present the imaging and survival outcomes of patients who underwent GKRS for intracranial metastases from NCSLC at a single institution.

Methods

Patient Characteristics

A single-institution retrospective analysis approved by the University of Pittsburgh institutional review board was conducted. This study evaluated survival outcomes in patients who underwent GKRS over a 10-year period between January 1, 2001, and December 31, 2010. During this time a total of 720 patients underwent SRS for intracranial NSCLC brain metastases. A total of 1004 SRS procedures (including retreatment for new disease), were conducted for the management of 3143 tumors. The outcome data were collected through medical record review and were analyzed retrospectively by neurosurgeons unaffiliated with the initial patient management. The median patient age was 63 years (range 27–96 years) at the time of SRS. Three hundred sixty-nine patients were men (51%). The histological NSCLC origin was adenocarcinoma in 386 patients (54%), squamous cell carcinoma in 111 patients (15%), and large cell carcinoma in 34 patients (5%) (Table 1). NSCLC was confirmed in an additional 189 patients (26%) pathologically, but a subtype remained unclear or unidentified.

There was a median interval of 1.5 months between primary diagnosis and presentation with intracranial metastases. Two hundred eighty-one patients (39%) had a synchronous diagnosis. Four hundred forty-nine patients (62%) presented with multiple metastases (range 2–23), and 271 patients (38%) presented with a solitary metastasis. Active systemic disease was present in 549 patients (76%) and extracranial metastases were identified in 271 patients (31%) at the time of SRS. Prior to SRS, 85 patients (12%) had undergone a craniotomy for gross-total resection of at least 1 tumor and 373 patients (52%) had received WBRT. In response to their systemic disease, 486 patients (68%) had received systemic chemotherapy and 227 patients (32%) had received both WBRT and chemotherapy. The median pretreatment Karnofsky Performance Scale (KPS) score was 90 (range 30–100).\(^{36}\) Stratification by recursive partitioning analysis (RPA) devised by the Radiation Therapy Oncology Group (RTOG) showed Class 1 in 61 patients (8%), Class 2 in 647 patients (90%), and Class 3 in 12 patients (2%).\(^{10,11}\)

Radiosurgery Technique

The expanded technical elements of this procedure have been detailed in our previous publications.\(^{14,22}\) Briefly, SRS was conducted as an outpatient procedure and intravenous conscious sedation was used. The Leksell stereotactic frame was applied after a local anesthetic agent was administered to the pin sites. High-resolution axial imaging (MRI unless contraindicated) was then conducted. Radiosurgery planning was calculated using a 3D conformal plan enveloping the entire enhancing tumor volume. This study spans the use of Leksell Gamma Knife models C, 4C, and Perfexion (Elekta AB).

Clinical and imaging follow-up were requested at 3-month intervals after SRS. If the intracranial disease burden increased as a result of new metastases or tumor growth, a repeat SRS procedure was recommended. The median aggregate target volume was 4.5 cm\(^3\) (range 0.1–88 cm\(^3\)\(^{36}\)), and the largest single metastatic deposit volume was 3.25 cm\(^3\) (range 0.1–78 cm\(^3\)\(^{36}\)). A median of 2 metastases (range 1–19) were treated at each radiosurgical procedure. The median marginal dose was 18 Gy (range 10–22 Gy) and the maximum dose was 34 Gy (range 20–50 Gy).

Factors influencing dose selection included but were not limited to: tumor characteristics (volume, number, and location) and previous radiation procedures. In general, the minimal margin dose for each tumor was 18–20 Gy. Dose reduction (e.g., 16 Gy) was used in select patients in whom WBRT had failed within the last 12 months. Margin doses were prescribed at various isodoses that ranged from 50% to 80% depending on the tumor volume. The use of higher margin doses, as suggested by RTOG guidelines, was not employed in this series since tumor control response as well as reduction in complication risks were achieved using the doses described above. This paradigm is based on our experience in excess of 4000 patients with various metastatic histological subtypes.

### TABLE 1. Summary of demographic and tumor characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>720</td>
</tr>
<tr>
<td>Age (yrs)</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>63</td>
</tr>
<tr>
<td>Range</td>
<td>27–96</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>369 (51)</td>
</tr>
<tr>
<td>Female</td>
<td>351 (49)</td>
</tr>
<tr>
<td>NSCLC subtype</td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>386 (54)</td>
</tr>
<tr>
<td>Squamous cell</td>
<td>111 (15)</td>
</tr>
<tr>
<td>Large cell</td>
<td>34 (5)</td>
</tr>
<tr>
<td>Undetermined</td>
<td>186 (26)</td>
</tr>
<tr>
<td>Metastases</td>
<td></td>
</tr>
<tr>
<td>Solitary</td>
<td>271 (38)</td>
</tr>
<tr>
<td>Multiple</td>
<td>449 (62)</td>
</tr>
<tr>
<td>Primary active</td>
<td>549 (76)</td>
</tr>
<tr>
<td>Extracranial metastases</td>
<td>271 (31)</td>
</tr>
<tr>
<td>KPS score</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>90</td>
</tr>
<tr>
<td>Range</td>
<td>30–100</td>
</tr>
<tr>
<td>No. w/ score ≥ 90</td>
<td>536 (74)</td>
</tr>
<tr>
<td>Prior WBRT</td>
<td>373 (52)</td>
</tr>
<tr>
<td>Prior surgery</td>
<td>85 (12)</td>
</tr>
<tr>
<td>Prior chemotherapy</td>
<td>486 (68)</td>
</tr>
<tr>
<td>RPA class</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>61 (8)</td>
</tr>
<tr>
<td>2</td>
<td>647 (90)</td>
</tr>
<tr>
<td>3</td>
<td>12 (2)</td>
</tr>
</tbody>
</table>

* Values are presented as the number patients (%) unless indicated otherwise.
Repeat radiosurgery was conducted 284 times in 174 patients. After the procedure, all patients received 20–40 mg of intravenous methylprednisolone. Patients were discharged from the hospital within 2–24 hours after the procedure. If any changes in neurological symptoms occurred after treatment, the patient was evaluated with imaging to assess for potential adverse radiation effects.

Statistical Analysis

Kaplan-Meier analysis was used to demonstrate correlations and for graphic interpretations of survival rates based on significant factors. Cox regression was used for univariate and multivariate analyses to calculate significant interactions between survival rates and related factors. A p value < 0.05 was defined as statistically significant. Comparisons between variable groups were performed where appropriate using the Fisher exact test. Variables analyzed in relation to survival included age, sex, KPS score, tumor (volume, number, and subtype) extracranial metastasis, primary status, margin dose, WBRT, resection and chemotherapy, and RPA.

Results

Survival

At study completion, 658 patients (91%) had died and 62 patients (9%) were alive. The median survival after NSCLC diagnosis was 19.9 months (range 1–178 months). Survival rates at 1, 2, and 5 years are based on Kaplan-Meier estimates. The 1-year survival after diagnosis was 70%, and at 5 years it was 16%. There was an increase in survival from diagnosis in patients with a controlled primary tumor (p < 0.001), younger age (p = 0.008), and female sex (p = 0.008). The time from diagnosis of NSCLC until the diagnosis of brain metastases was prolonged by systemic chemotherapy treatment (p = 0.009). The median survival from the diagnosis of brain metastasis was 12.6 months (range 1–175 months). Statistically, this represented 52% survival at 1 year, 26% at 2 years, and 12% at 5 years. The median survival after SRS was 8.5 months (0.5–158 months). This corresponded to a 6-month survival of 61%, 1-year survival of 39%, 2-year survival of 21%, and 5-year survival of 10%.

Survival time from SRS decreased as age increased (p < 0.001). The median survival was 11.2 months for age < 60 years and 7.1 months for age ≥ 60 years. Survival was increased for female patients and the presence of a controlled primary tumor (p = 0.011 and p < 0.001, respectively). A higher KPS score at SRS correlated with an increased survival time (p < 0.001). A KPS score ≥ 90 was associated with a median survival of 9.5 months compared with 5.2 months for KPS score < 90. A median tumor margin dose > 18 Gy increased survival (p = 0.006). Patients who required multiple SRS procedures had improved survival (p < 0.001). RPA analysis delineated median survivals after SRS of 14 months in Class 1, 8 months in Class 2, and 2 months in Class 3 (p < 0.001) (Fig. 1).

Survival between histological subtypes differed significantly. The median survival from SRS for patients with adenocarcinoma was 10.5 months compared with those with squamous cell carcinoma, which was 5.2 months (p = 0.023) (Fig. 2). The large cell subtype was consistent with survival of patients with adenocarcinoma (median survival of 10 months). Survival after metastasis diagnosis and after SRS decreased as the aggregate tumor volume increased (p = 0.001 and p < 0.001, respectively). A median survival of 10.3 months was associated with an aggregate tumor volume < 5 cm³ compared with a median survival of 6.4 months for patients whose total tumor volume was ≥ 5 cm³ (Fig. 3). The volume of the largest
single metastatic tumor was also significant for survival after SRS (p = 0.001). The presence of multiple brain metastases was a negative predictor of survival (p = 0.017). The survival from SRS based on the number of metastases was 10.3 months for a solitary lesion, 8.5 months for 2–4 metastases, and 6.1 months for ≥ 5 metastases. The survival from initial brain metastasis diagnosis was 14.6 months for 1 metastasis, 11.6 months for 2–4 metastases, and 11.5 months for ≥ 5 metastases (Fig. 4).

The use of prior WBRT negatively correlated with survival after SRS (p = 0.003). The median survival was 9.8 months in patients who had not received WBRT and 7.5 months for patients treated with prior WBRT (Fig. 5). Statistical significance was lost when WBRT was calculated based on survival from diagnosis of brain metastasis (p = 0.955). Patients without prior WBRT underwent SRS at a median of 0.9 months after diagnosis of brain metastasis compared with 3.3 months in the WBRT-treated group. The percentage of patients receiving prior WBRT was associated with the number of metastases, as 30% of patients with a single metastasis, 53% of patients with 2–4 metastases, and 68% of patients with ≥ 5 metastases had already undergone WBRT. This delayed SRS in many patients, as the time from brain metastasis diagnosis to SRS was a median of 1.3 months in solitary metastases, 1.8 months in patients with 2–4 metastases, and 3 months in patients with ≥ 5 metastases. WBRT was used more frequently in patients with multiple metastases (p < 0.001), in patients with an active primary tumor (p = 0.011), and in patients with larger tumor volumes (p = 0.005).

This study investigated outcomes over 10 years. To ascertain whether any changes in referral pattern impacted the results, the initial 5 years and the final 5 years were analyzed and compared. Patients with multiple metastases were treated more frequently in the final 5 years of the study (p < 0.001). The KPS score of patients at the time of SRS was also statistically lower in the final 5 years (p < 0.001). In addition, some variables approached, but did not reach, significance. These included a higher rate of prior WBRT being used in the initial 5 years of the study (p = 0.073). The median survival after SRS was 1.7 months longer in the initial 5 years (9.2 months) than the final 5 years (7.5 months) (p = 0.105). A similar finding was identified for survival from the time of brain metastasis diagnosis (p = 0.078).

Tumor Control

Follow-up with imaging was available for 403 patients (56%), with 1763 treated metastases at a median of 8 months (range 1–124 months). The local tumor control rate was 92.8% based on imaging follow-up. The 1-year product limit local control rate per metastasis treated was calculated at 93%. This corresponded to local tumor recurrence developing in 80 patients (20%). Therefore, 61 patients (15%) had at least 1 metastasis requiring repeat SRS, or palliative management, and 19 patients (5%) required resection due to tumor progression or refractory peritumoral edema. Post-SRS palliative WBRT was administered in 31 patients. The tumor subtype was identifiable in 79% of patients with follow-up. Local tumor control was 94% (based on 1319 tumors) in the adenocarcinoma group, 92% (based on 223 tumors) in the squamous cell group, and 92% (based on 139 tumors) in the large cell group. This represented local recurrence in 19% of adenocarcinoma patients, in 27% of squamous cell patients, and in 28% of large cell patients.

Distant brain metastases outside the original treatment field requiring repeat SRS occurred in 42% of patients with follow-up. Of patients with adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, 51%, 21%, and 35%, respectively, had intracranial metastases. At the time of analysis 683 patients had died, 27% of whom died as result of progressive intracranial disease. This reflected a rate for neurological death of 25% for adenocarcinoma, 34% for squamous cell carcinoma, and 25% for large cell carcinoma based on subtype.

Discussion

Survival

Metastatic tumors are the most common intracranial neoplasms and are increasing in frequency, with an annual incidence of 170,000–200,000 in the United States. These lesions are invariably associated with a decreased survival and occur in upward of 30% of patients with NSCLC. In this study, the median survival time after diagnosis of NSCLC metastases was 12.6 months, with a survival after SRS of 8.5 months. The 1-year survival rate after SRS was 39% and the 5-year survival was 10%. These results are consistent with previously published studies. There were multiple statistically significant factors that influenced survival, including sex, age, primary status, prior WBRT, KPS score, marginal dose, and tumor characteristics such as histology subtype, tumor volume, and number of metastases. NSCLC provides an overarching tumor classification, but our understanding of tumor biology and genetics, and
even clinical analysis, indicates that each histological subtype is a distinct entity. The standard NSCLC histological breakdown is adenocarcinoma in 48% of patients, squamous cell in 25%, large cell in 3%, and other in 24%. The frequency of brain metastases in patients with adenocarcinoma and large cell carcinoma is reported to be higher than that for squamous cell carcinoma. This is reflected in our study as 54% of our patients had adenocarcinoma, 15% had squamous cell carcinoma, and 5% had large cell carcinoma. Furthermore, distant metastases occurred far more frequently in the adenocarcinoma group. The tumor control rate was relatively consistent across the subtypes. However, survival within the subtypes was significantly different as patients with adenocarcinoma and large cell carcinoma both had a median survival of 10 months, whereas those with squamous cell carcinoma had a survival of only 5 months. Patients with squamous cell carcinoma also had a higher rate of neurological death at 34%, compared with 25% for both adenocarcinoma and large cell metastases. This is comparable to the recent report by Kuremsky et al., who reached a similar conclusion regarding the value of prognostic analysis based on tumor subtype.

The use of WBRT and its relationship to intracranial metastastic disease has been under ever-increasing scrutiny for many cancer types. Although the palliative effects of WBRT have been well documented, the risks of cognitive decline and dementia have become more prominent as medical advances extend survival. Recent publications have indicated that WBRT has no survival benefit, no improvement in functional independence, and a negative impact on quality of life. In our study, the survival from the time of SRS was shorter by longer than 2 months in the WBRT-treated group. However, the statistical significance was neutralized when the survival from diagnosis of brain metastasis was analyzed. This can be accounted for by a time delay until SRS, since the delay was a median of 1 month for patients treated without WBRT whereas the delay was a median of 3.3 months for those treated with WBRT.

The presence of a solitary metastasis was associated with an increased survival, which is well documented in the literature. In regard to multiple metastases, there

**FIG. 4.** Left: Kaplan-Meier curve depicting survival from SRS based on the number of metastases treated (p = 0.017). Right: Kaplan-Meier curve depicting survival from intracranial metastasis diagnosis based on the number of metastases treated (solid line, solitary metastasis; dotted line, 2–4 metastases; dashed line, ≥5 metastases). The patients remaining in the equations are depicted at each time point. Graph truncated to 10 years.

**FIG. 5.** Kaplan-Meier curve depicting survival from SRS based on whether patients had received WBRT treatment (p = 0.003). The patients remaining in the equations are depicted at each time point. Graph truncated to 10 years.
has been a progressive increase in the number of tumors that are managed by SRS. In this study, the median survival from SRS was 10.3, 8.5, and 6.1 months for 1, 2–4, and ≥5 metastases, respectively. The frequent utilization of prior WBRT in patients with multiple metastases resulted in a median time delay from intracranial metastasis diagnosis until SRS of 1.8 months for patients with 2–4 metastases and a delay of 3 months for the those with ≥5 metastases. This resulted in essentially equivalent median survival from diagnosis of intracranial metastasis of 11.5 months. Yamamoto et al. and Serizawa et al. investigated patients with up to 10 metastases who did not undergo prior WBRT, which allowed for SRS to be performed within 6 weeks of diagnosis. These studies showed no statistical survival advantage between subgroups with more than 1 metastasis.\textsuperscript{29,35} The involvement of factors such as patient age, KPS score at SRS, and RPA class appear to have a larger impact on survival predictions than the number of metastases.\textsuperscript{3,12,28}

Tumor volume was a significant factor in patient survival, accounting for a 1-year survival increase of 14% after SRS. The clearest separation was demonstrated at <5 cm\(^3\) or ≥5 cm\(^3\) with an increase in median survival of 4 months. The statistical significance of tumor volume and its negative impact on overall survival has been indicated in the literature.\textsuperscript{2,25} The aggregate tumor volume was not a factor in tumor control in this paper. However, the rate of tumor control in larger metastases based on published data remains well in excess of 85% for tumors larger than 6 cm\(^3\).\textsuperscript{10,26} In addition, a reduction in tumor volume after SRS has been documented to occur in 46% of NSCLC metastases.\textsuperscript{7} Tumor volume is known to impact neurological and cognitive functioning and is likely a more important survival factor than number of tumors.

SRS has previously demonstrated a high local control rate of brain metastases, almost independent of the cell of origin. In this study, the local tumor control rate was 92.8%. The need for surgical treatment after SRS was limited in this study to less than 5% of patients, which is consistent with the analysis by Xu et al.\textsuperscript{34} Distant brain metastases requiring retreatment occurred in 42% of patients; 51% of these patients had undergone prior WBRT. Previous studies have indicated that active systemic disease results in an increased risk of distant metastases, which is consistent with our analysis.\textsuperscript{1,10} This ongoing risk of new metastases supports the need for frequent clinical and imaging observation of these patients regardless of the treatment paradigm selected. This study was truncated at 10 years with the underlying understanding that referral patterns and treatment paradigms evolve. The treatment of multiple brain metastases by SRS has increased dramatically over time, as WBRT has trended in the opposite direction. Therefore, as expected, an increased percentage of patients with multiple metastases were identified in the final 5 years of the study. A management shift is also evident in that more patients with a lower KPS score were treated in the final 5 years. The influence of the KPS score alone after SRS in the Kaplan-Meier curves was >4 months (KPS score ≥90). Therefore, patient selection and a more aggressive approach regarding KPS score may be contributing factors to a slightly lower yet nonstatistically significant reduction in survival between the initial and final 5 years of this study.

**Study Limitations**

Although all patients were prospectively entered into a database at the time of SRS, this report is a retrospective review of outcomes. We acknowledge the inherent limitations of a retrospective study and the possibility of referral bias. In an attempt to offset the variations in referral patterns and treatment paradigms, such as the use of radiosurgery for treating increasing numbers of metastases, these results were analyzed and a 10-year time period was used. Some patients who had undergone WBRT were referred because of inadequate tumor response after WBRT.

**Conclusions**

Intracranial metastases from NSCLC are common and are associated with a poor prognosis. Aggressive management of both intracranial and systemic disease offers patients improved survival. This study demonstrates a local tumor control rate after GKRS of 92.8%. The variables affecting survival were multifactorial in this analysis but included tumor volume and histological subtype. Early recognition of intracranial metastases, coupled with early SRS and repeat patient imaging to define new disease, are imperative.

**Acknowledgments**

We acknowledge Xiaoran Zhang, Jee-Hong Kim, Seyed H. Mousavi, and Douglas Kondziolka.

**References**


Author Contributions
Conception and design: Kanoh, Bowden. Acquisition of data: Bowden, Caparosa, Park. Analysis and interpretation of data: Bowden. Drafting the article: Kanoh, Bowden, Lunsford. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Kanoh. Statistical analysis: Bowden. Study supervision: Kanoh.

Correspondence
Hideyuki Kanoh, Department of Neurological Surgery, University of Pittsburgh, Ste. B-400, UPMC Presbyterian, 200 Lothrop St., Pittsburgh, PA 15213. email: kanoh@upmc.edu.